



Nonprofit corporations and independent licensees  
of the Blue Cross and Blue Shield Association

## Provider alert

Blue Cross commercial, Medicare Plus Blue<sup>SM</sup>,  
BCN commercial and BCN Advantage<sup>SM</sup>

Categories: Billing/claims/coding, COVID-19, Pharmacy

Date posted: Dec. 13, 2022

---

## Monoclonal antibody COVID-19 infusion Bebtelovimab no longer payable

Per the U.S. Food & Drug Administration, Bebtelovimab is no longer authorized for use in the U.S., effective Nov. 30, 2022. As a result, claims for procedure codes Q0222, M0222 and M0223 are no longer payable for dates of service on or after Nov. 30, 2022. These claims will reject as provider liable.

This change affects Blue Cross commercial, Medicare Plus Blue, BCN commercial and BCN Advantage members.

For more information, see the [FDA Announces Bebtelovimab is Not Currently Authorized in Any US Region\\*](#) page of the FDA website.